225 related articles for article (PubMed ID: 17237402)
1. Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses.
Lou Y; Liu C; Kim GJ; Liu YJ; Hwu P; Wang G
J Immunol; 2007 Feb; 178(3):1534-41. PubMed ID: 17237402
[TBL] [Abstract][Full Text] [Related]
2. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
4. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity.
Hermans IF; Ritchie DS; Yang J; Roberts JM; Ronchese F
J Immunol; 2000 Mar; 164(6):3095-101. PubMed ID: 10706699
[TBL] [Abstract][Full Text] [Related]
5. [Anti-lung cancer effect of myeloid and plasmacytoid dendritic cell combined vaccines loaded with tumor cell lysates in vitro].
Tan JF; Zhong CH; Chen J; Guo QW; Kuang J; Zhang JH
Zhonghua Zhong Liu Za Zhi; 2019 Jul; 41(7):501-507. PubMed ID: 31357836
[No Abstract] [Full Text] [Related]
6. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
[TBL] [Abstract][Full Text] [Related]
7. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
8. Myeloid and plasmacytoid dendritic cell combined vaccines loaded with heat-treated tumor cell lysates enhance antitumor activity in murine lung cancer.
Chen H; Tan J; Li X; Li H; Wu W; Wu Y; Zhang J; Gu L
Oncol Lett; 2021 Feb; 21(2):90. PubMed ID: 33376523
[TBL] [Abstract][Full Text] [Related]
9. Subversion of plasmacytoid and myeloid dendritic cell functions in chronic HCV infection.
Szabo G; Dolganiuc A
Immunobiology; 2005; 210(2-4):237-47. PubMed ID: 16164031
[TBL] [Abstract][Full Text] [Related]
10. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
Wargo JA; Schumacher LY; Comin-Anduix B; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS; Ribas A
Cancer Gene Ther; 2005 Jun; 12(6):516-27. PubMed ID: 15775996
[TBL] [Abstract][Full Text] [Related]
11. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
12. Antigen gene transfer to human plasmacytoid dendritic cells using recombinant adenovirus and vaccinia virus vectors.
Bontkes HJ; Ruizendaal JJ; Schreurs MW; Kramer D; Meijer CJ; Hooijberg E
Cell Oncol; 2005; 27(3):175-82. PubMed ID: 16037638
[TBL] [Abstract][Full Text] [Related]
13. Independent of plasmacytoid dendritic cell (pDC) infection, pDC triggered by virus-infected cells mount enhanced type I IFN responses of different composition as opposed to pDC stimulated with free virus.
Frenz T; Graalmann L; Detje CN; Döring M; Grabski E; Scheu S; Kalinke U
J Immunol; 2014 Sep; 193(5):2496-503. PubMed ID: 25070849
[TBL] [Abstract][Full Text] [Related]
14. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
[TBL] [Abstract][Full Text] [Related]
15. The plasmacytoid dendritic cells evoke Salmonella-specific CTL effector response.
Murúa-López CDC; González-Orozco M; López-Moreno HS
Biomedica; 2019 Aug; 39(Supl. 2):172-181. PubMed ID: 31529843
[TBL] [Abstract][Full Text] [Related]
16. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo.
Stober D; Jomantaite I; Schirmbeck R; Reimann J
J Immunol; 2003 Mar; 170(5):2540-8. PubMed ID: 12594280
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
Xie Y; Bai O; Zhang H; Li W; Xiang J
Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.
Gabrilovich DI; Ciernik IF; Carbone DP
Cell Immunol; 1996 May; 170(1):101-10. PubMed ID: 8665590
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help.
McCoy KD; Hermans IF; Fraser JH; Le Gros G; Ronchese F
J Exp Med; 1999 Apr; 189(7):1157-62. PubMed ID: 10190907
[TBL] [Abstract][Full Text] [Related]
20. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
Tanaka Y; Koido S; Ohana M; Liu C; Gong J
J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
